Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) shares were up 13.2% on Thursday . The company traded as high as $0.37 and last traded at $0.36. Approximately 85,764,556 shares were traded during mid-day trading, an increase of 13% from the average daily volume of 76,209,492 shares. The stock had previously closed at $0.32.
Wall Street Analyst Weigh In
Separately, StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research note on Saturday. They set a "hold" rating on the stock.
Get Our Latest Research Report on TNXP
Tonix Pharmaceuticals Stock Up 17.0 %
The stock has a market cap of $71.60 million, a price-to-earnings ratio of -0.01 and a beta of 2.02. The business's 50 day moving average is $0.28 and its 200-day moving average is $0.28. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The firm had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. On average, sell-side analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. PFG Investments LLC bought a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 218,003 shares of the company's stock, valued at approximately $72,000. PFG Investments LLC owned approximately 0.12% of Tonix Pharmaceuticals as of its most recent SEC filing. 82.26% of the stock is owned by hedge funds and other institutional investors.
About Tonix Pharmaceuticals
(
Get Free Report)
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Further Reading
Before you consider Tonix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.
While Tonix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
